HIKAL
NSEHikal Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹183.99
7.84 (4.45%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹2.27K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹146.25+25.8%
52W High₹386.25-52.4%
Current Price
₹183.99
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹147.19
Upper Circuit₹220.79
Reference Price
₹183.99
Investment Checklist
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹213.06
Head and Shoulders on 1D (BREAKOUT CONFIRMED) — target ₹213.06
Composite score -63.01 (STRONG_SELL) with 84.5% confidence
Trend: Price below most MAs — downtrend | Bearish MA stack (20<50<200)
SuperTrend(10,3): Price below SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
85%
Trend
BEARISH
BEARISH
Price below most MAs — downtrend | Bearish MA stack (20<50<200)
EMA20
191.13
EMA50
191.74
EMA200
224.17
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows3
Lower Highs4
Lower Lows6
Support & Resistance Levels
Resistance (Above)
₹194.40
₹199.44
₹218.00
₹222.80
₹228.00
Support (Below)
₹179.50
₹177.35
₹171.25
₹146.25
Volume Analysis
TrendDECREASING
Change-57.30%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹182.15
3% Risk₹178.47
5% Risk₹174.79
7% Risk (Custom)
₹171.11Technical Levels
1x ATR (Volatility)₹175.79
2x ATR (Swing)₹167.59
3x ATR (Trend)₹159.39
Immediate Support₹179.50
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Sep '25 |
|---|---|---|---|---|
| Revenue | ₹438.9 Cr | ₹550 Cr | ₹371.3 Cr | ₹316.2 Cr |
| Net Profit | ₹17.2 Cr | ₹50.2 Cr | ₹-22.4 Cr | ₹-34.9 Cr |
| EPS | ₹1.39 | — | ₹-1.82 | ₹-2.83 |
| Operating Profit | ₹75.7 Cr | ₹121.4 Cr | ₹26.1 Cr | ₹9.1 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 17 Feb 2026 | Interim Dividend - Re 0.20 Per Share | INTERIM_DIVIDEND |
| 02 Sept 2025 | Dividend - Rs 0.80 Per Share | DIVIDEND |
| 07 Feb 2025 | Interim Dividend - Re 0.60 Per Share | INTERIM_DIVIDEND |
| 10 Sept 2024 | Annual General Meeting | AGM |
| 04 Sept 2024 | Dividend - Re 0.60 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for HIKAL
View AllNEWS
neutral
Business Standard - Markets 16d ago
Hikal consolidated net profit declines 71.31% in the March 2026 quarter
Sales decline 6.00% to Rs 517.00 crore
HIKALHealthcare
positive
CNBC TV18 - Markets 16d ago
Hikal Q4 results muted; sequential recovery driven by crop protection growth
Hikal reported muted Q4 earnings with profit and margins under pressure, though the company saw sequential recovery in revenue and profitability led by stronger crop protection performance and operational improvement.
HIKALPUNJABCHEMChemicalsHealthcare
positive
Moneycontrol NaNd ago
Stocks to Watch Today: Physicswallah, Swiggy, Q-Line Biotech, Lupin, Wockhardt, Ashok Leyland, GMR Airports, PG Electroplast, West Coast Paper in focus on 29 May
Stocks in News, 29 May: Stocks like Physicswallah, Ashok Leyland, Deepak Fertilisers & Petrochemicals Corporation, Bata India, PC Jeweller, GMR Airports, PG Electroplast, Gabriel India, Hikal, Varroc Engineering, Enviro Infra Engineers, HG Infra Engineering, Swiggy, and Indoco Remedies will be in focus on May 29.
ASHOKLEYBATAINDIADBEILDEEPAKFERTEIELENGINERSINENVIROFOCUSGABRIELGMRAIRPORTHGINFRAHIKALIGPLINDOCOINFRAJKPAPERLUPINMBELPCJEWELLERPGELPWLSWIGGYVARROCWOCKPHARMAWSTCSTPAPRAutomobile and Auto ComponentsCapital Goods